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AMPA receptor potentiating drugs, ampakines)4. mGlu5 antag-
onists have been tested in ASD associated with fragile X syn-
drome, and showed promise in a subgroup of patients5.
GABAergic agents, such as the GABA-B receptor agonist arba-
clofen (STX209), have shown some effect on irritability and
social withdrawal in ASD children6.
The peptide hormone oxytocin is important in social cogni-
tion and behavior. In ASD adults, acute intravenous administra-
tion of oxytocin reduced repetitive behaviors7 and improved
accuracy of recognizing emotions in speech over time8. Intra-
nasal administration improved social cognition in children,
adolescents and adults with ASD9. A vasopressin 1a receptor
antagonist had some effect on speech recognition of emotions
such as fear and lust in high-functioning ASD adults.
Insulin-like growth factor 1 (IGF-1) is important in central ner-
vous system maturation, development and connectivity, that are
perturbed in ASD. Studies in Shank-3 deficient mice that model
Phelan-McDermid syndrome (PMS), which may be associated
with some cases of ASD, indicated that IGF-1 may reverse structur-
al changes in ionotropic glutamate receptors, functional synaptic
plasticity changes, and excitation/inhibition imbalance. A clinical
trial with recombinant human IGF-1 in PMS children showed
improvement in social impairment and restricted behaviors10.
Agents modulating the immune system have been tested in
ASD. The immune response induced by the whipworm Trichu-
ris suis ova has shown benefit on the repetitive behavior
domain in adult ASD. Immunosuppressive and protein synthe-
sis inhibiting drugs such as the mTOR inhibitor rapamycin have
been shown to improve social deficits in some forms of ASD.
The alpha-7 nicotinic acetylcholine receptor (nACR) gene is
associated with autism and ADHD. nACR drugs tested in clinical
trials include mecamylamine, transdermally administered nico-
tine, and donepezil. Some alpha-7 nACR antagonists such as gal-
antamine have shown promise in animal models and clinical trials.
Drugs modulating the cannabinoid system, such as canna-
bidiol, have been found effective in childhood epilepsy, and
may be worth studying in ASD due to their anti-anxiety, anti-
epileptic, immunomodulating and cognitive-enhancing effects
and good safety. Interestingly, social reward and oxytocin
induce release of endocannabinoids in nucleus accumbens. In
ASD animal models, cannabidiol has some impact on social
deficits, repetitive behaviors and irritability.
Complementary and alternative medicine (CAM) treat-
ments have been tested in ASD. However, they are not strictly
regulated and have not been studied in large-scale clinical
trials. Therefore, their safety and efficacy is not well deter-
mined. CAM treatments may complement rather than replace
proven therapies for ASD. Melatonin may be used for sleep
disorders, omega-3 fatty acids for reducing repetitive behav-
iors and improving sociability. Vitamin B12 supplements are
believed to protect against the oxidative damage in ASD. Cur-
cumin, an active ingredient of turmeric, may be beneficial in
ASD, perhaps owing to its anti-oxidant and anti-inflammatory
properties. Probiotics such as yogurt may have effects on the
gut microbiome and on pro-inflammatory cytokines that may
play a role in the pathogenesis of ASD.
In summary, the enormous heterogeneity in ASD complicates
development of new pharmacotherapies. Personalized treat-
ments are desirable, and studies of syndromal orphan popula-
tions may accelerate drug development. Design of future clinical
trials needs to address patient stratification on the basis of bio-
markers or etiology (for example, immune-inflammatory) and
target populations stratified by clinical symptoms.
New pharmacotherapies such as oxytocin/vasopressin antag-
onists, anti-inflammatory agents, IGF-1, drugs regulating exci-
tation/inhibition balance, protein synthesis inhibitors, and
microbiome-targeting drugs may be of particular promise.
Existing drugs such as anticonvulsants, SSRIs and atypical
antipsychotics may be beneficial in some patients. It is impor-
tant to test the effectiveness of drugs in younger children who
may benefit most from early intervention. The ultimate goal of
ASD pharmacotherapy will be to match the treatment to the
underlying molecular mechanisms in individual patients.
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Nonmedical use of prescription drugs in adolescents and young
adults: not just a Western phenomenon
Nonmedical prescription drug use, generally defined as use
without a prescription or use for reasons other than what the medi-
cation is intended for, is a global concern, primarily driven by the
high and rising phenomenon of nonmedical use of prescription
opioids in young populations. Prescription drugs are legal and
hence tend to be more easily available than most illegal drugs.
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Nonmedical use merits particular attention given the high
degree of abuse potential1 and numerous ill-health conse-
quences, that vary depending on the drug. Nonmedical use of
prescription stimulants can lead to irregular heart rate, hyper-
tension, cardiovascular system failure, stroke and seizures,
while nonmedical use of prescription opioids can cause respi-
ratory suppression and overdose2. Most of drug-related deaths
worldwide are due to either prescription opioid or heroin over-
doses. A recent review has illustrated worldwide increased
rates of deaths from prescription opioids3, with the exception
of Australia. In Europe, prescription opioids account for three-
quarter of overdose deaths, which represent 3.5% of total deaths
among 15-39 year olds.
Nonmedical use of stimulants and prescription opioids
among adolescents and young adults has also been linked to
increased harmful use of other substances4, reporting of psychi-
atric symptoms, psychiatric disorders and suicidal ideation5.
Despite the undisputed worldwide concern, it is important
to note the variability in the prevalence/patterns of nonmedi-
cal use of prescription drugs among young people. In the US,
according to the 2014 National Survey on Drug Use and Health,
past-year nonmedical use of prescription drugs (opioids, stimu-
lants, tranquilizers and sedatives) was reported by 6.2% of
12-17 year-olds and 11.8% of 18-25 year-olds, mainly driven by
nonmedical use of prescription opioids, which has remained
stable in the past decade despite rising trends since the late
1990s. Data from the 2012 Canadian Alcohol and Drug Use Mon-
itoring Survey showed that 4.9% of 15-24 year olds were past-
year nonmedical users of the above cited prescription drug clas-
ses. Data from the 2013 Australian National Household Survey
showed an increase in nonmedical use of prescription drugs
since 1998, particularly among 14-19 year olds; the 2013
past-year estimates were 4% among 14-19 year olds, and
5.8% among 20-29 year olds. While comparability is hindered
by the varying methodologies, definitions, and age catego-
rizations, data clearly supports the global concern for the non-
medical use of prescription drugs among young vulnerable
populations.
General household population data among young popula-
tions in other countries are not as readily available, but there
is data from school-based and college-based surveys in
Europe, Latin America, Asia and the Middle East. In Europe,
data from 36 countries collected as part of the 2011 European
School Survey Project on Alcohol and other Drugs showed
that, on average, 6% of European school students (mean age
of 15.8 years) reported lifetime nonmedical use of tranquil-
izers (data on other drug classes are unavailable).
Data on high school or university students from the Middle
East or Arab world indicate that nonmedical use of prescrip-
tion drugs warrants closer attention. In Beirut, Lebanon, past-
year nonmedical use of any prescription drugs was 21.6%
among private university students, and 10% among high
school students. In both populations, prescription opioids
were the drugs most commonly used nonmedically. In Saudi
Arabia, a recent school-based survey showed a lifetime preva-
lence of 7.2% for the nonmedical use of any prescription drug.
In Brazil, the most recent national school-based survey,
conducted in 2010, showed that the past-year prevalence of
nonmedical use of prescription stimulants among middle/
high school students in public and private schools was 1.6%
and 2.2%, respectively. Only lifetime data on nonmedical pre-
scription opioid use was collected (0.3% of all middle/high
school students). One study from Southern China conducted
in 2007-2009 revealed that 6% of the middle/high school stu-
dents had tried any prescription medication nonmedically,
mostly opioids, followed by cough medicine with codeine. A
2012 high school survey from Chongqing, China reported a
lifetime prevalence of 11.3% for the nonmedical use of pre-
scription opioids only. For comparison purposes, data from
the 2015 US Monitoring the Future school and college-based
surveys showed that 12.8% of 12th graders used any prescrip-
tion drugs nonmedically.
It is important to shed light on important socio-demographic
differences. College-based studies exclude significant propor-
tions of minority or low socio-economic status young adults,
who are at higher risk of developing a prescription drug use dis-
order once they start using the drugs. Evidence on gender differ-
ences among adolescents and young adults has been mixed:
some studies have found no difference; others have found a
higher prevalence in males or in females6,7. Early age of initia-
tion of nonmedical use has been associated with higher likeli-
hood of ill-health outcomes, including a higher probability of
developing substance use disorders8. Individuals with previous
nonmedical use of prescription opioids may be at greater risk of
heroin use and heroin dependence9. Motives for nonmedical
use also vary (i.e., to get high; to self-medicate), leading to the
presence of several heterogeneous subgroups of nonmedical
users that are at varying risks of other substance use10.
Worldwide comparisons are hampered by the variations in
the study methodologies, including definitions of nonmedical
use or prescription drugs included. The impact is also different
given the varied availability and cultural acceptance of the
drugs worldwide. Prescription drug monitoring programs,
recently implemented in the US, Canada and Australia, are not
widely available globally and, where available, there is uneven-
ness in how they operate. Today, the biggest challenge is bal-
ancing a country’s need to make available prescription drugs
to those in need (i.e., those with chronic pain) while simulta-
neously curbing diversion and nonmedical use. Pharmacists
in some countries struggle between providing medical advice
and service to those who cannot afford a doctor’s prescrip-
tion while meeting the requirements of their governmental
regulations. Another challenge is controlling the top most
reported sources of supply, including parents, doctors and
friends, highlighting the need to target multiple sources
simultaneously.
The greater “social acceptance” for using these medications
(versus illegal substances) and the misconception that they
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are “safe” may be contributing factors to their misuse. Hence,
a major target for intervention is the general public, including
parents and youth, who must be better informed about the
negative consequences of sharing with others medications
prescribed for their own ailments. Equally important is the
improved training of medical practitioners and their staff to
better recognize patients at potential risk of developing non-
medical use, and to consider potential alternative treatments
as well as closely monitor the medications they dispense to
these patients.
The United Nations Office of Drugs and Crime is already
assisting several governments in collecting epidemiologic data
more efficiently as well as developing monitoring and training
programs that ensure these drugs are available to those who
need them while strictly avoiding diversion for nonmedical
purposes.
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The concept of basic symptoms: its scientific and clinical relevance
The concept of basic symptoms originates from retrospective
descriptions of the prodromal phase of schizophrenia, pub-
lished in the first half of the 20th century and continuously
developed through its second half1. It was not until the mid
1990s, however, that basic symptoms attracted a broad attention
within two main lines of research: an empirical approach to ear-
ly detection of psychosis2 and a heuristic approach to define the
Gestalt of schizophrenia by so-called “self-disorders”3.
Basic symptoms are subtle, subjectively experienced distur-
bances in mental processes including thinking, speech, atten-
tion, perception, drive, stress tolerance, and affect1,2,4. Following
training, they can be reliably assessed with a clinical interview
from age 8 onwards using the youth and adult version of the
Schizophrenia Proneness Instrument5,6 (available at www.
basicsymptoms.org). They have been reported in all stages of
psychotic disorders, including prodromes and acute states of
first episode and relapse, as well as residual states1,2,4.
Basic symptoms are regarded as an immediate symptomatic
expression of the neurobiological processes underlying psycho-
sis and the earliest form of self-experienced symptoms – hence
the term “basic”. In contrast, attenuated and overt psychotic
symptoms are assumed to develop later, as a result of poor cop-
ing with initial symptoms, such as basic symptoms, or stressors,
when a vulnerable individual’s protective mechanisms are over-
strained1,4. With its focus on the emerging disorder, the concept
of basic symptoms has been linked to a better understanding of
the origins of psychoses, in particular schizophrenia, and to an
improvement of their (early) diagnosis and treatment.
Initially, two criteria for the identification of basic symp-
toms were developed: cognitive-perceptive basic symptoms
(COPER) and cognitive disturbances (COGDIS)1,2,4. COGDIS
requires two of nine cognitive basic symptoms to occur at least
once per week and is increasingly used as a clinical high-risk
criterion in addition to ultra-high risk criteria2,7. The first
meta-analysis comparing various clinical high-risk criteria
found pooled conversion rates in COGDIS-defined samples of
up to 61% at follow-ups of more than four years. Medium- and
long-term pooled conversion rates of COGDIS samples were
significantly higher than those of ultra-high risk criteria sam-
ples7. Thus, the European Psychiatric Association recommended
ultra-high risk criteria and COGDIS to be used alternatively
for psychosis risk assessment7. However, the presence of both
COGDIS and ultra-high risk criteria appears to increase psychosis
predictability compared to either criterion alone2.
In spite of their neurobiological conceptual foundation,
basic symptoms have only recently been considered in neuro-
biological studies of psychosis. Several correlates of these
symptoms in psychotic and clinical high-risk individuals have
been reported. These included changes in event-related poten-
tials, neural oscillations, neurotransmitter systems, and large-
scale networks as assessed with functional magnetic resonance
imaging4. However, there is a need for further studies in clinical
and non-clinical samples exploring the neurobiological corre-
lates of individual basic symptoms and their relevance to the
development of psychosis4.
The basic symptoms concept has informed research on altera-
tions of the very experience of the self as a core feature of schizo-
phrenia3,8. Within this line of research, basic symptoms are an
integral part of the so-called “anomalous self-experiences”,
“(basic) self-disturbances” or “self-disorders”3. Starting with
E. Bleuler’s characterization of schizophrenia as “a loss of unity of
the personality”, self-disturbances have always had a central role
in the concept of schizophrenia, being explored by authors such
as Minkowski and Blankenburg. Currently, alterations in self-
disturbances, including the “development of an integrated sense
of self” are believed to have common underlying neurobiological
mechanisms8. Basic symptoms offer an empirical approach to
test related hypotheses, such as perceptual incoherence or
104 World Psychiatry 16:1 - February 2017
